Details for Patent: 9,474,780

« Back to Dashboard

Which drugs does patent 9,474,780 protect, and when does it expire?

Patent 9,474,780 protects MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN, ZEPBOUND, ZEPBOUND (AUTOINJECTOR), and ZEPBOUND KWIKPEN, and is included in two NDAs.

This patent has eighty patent family members in forty-six countries.

Summary for Patent: 9,474,780

Title:	GIP and GLP-1 co-agonist compounds
Abstract:	The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).
Inventor(s):	Bengt Krister Bokvist, Tamer Coskun, Robert Chadwick Cummins, Jorge Alsina-Fernandez
Assignee:	Eli Lilly and Co
Application Number:	US14/987,791
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,474,780
Patent Claim Types: see list of patent claims	Use; Composition;

United States Patent 9,474,780: Tirzepatide Claim Scope, Patent Expiration, and Competitive Landscape

US Patent No. 9,474,780 covers a class of acylated GLP-1-related peptide compounds, including the active ingredient tirzepatide. The broadest practical commercial claim is claim 10, which covers the tirzepatide molecule with two Aib substitutions, a gamma-glutamyl spacer, an 18-carbon diacid chain, and a C-terminal amide. The patent also covers pharmaceutical compositions and methods of treating type 2 diabetes, including combination therapy with established antidiabetic medicines.

The patent is assigned to Eli Lilly and Company and issued on October 25, 2016. Its nominal patent term runs to approximately August 5, 2034, subject to any applicable patent-term adjustment or extension. The patent is one component of Lilly's broader tirzepatide estate, which includes later composition, formulation, manufacturing, and regulatory-exclusivity rights.

What drug does US Patent 9,474,780 protect?

US 9,474,780 protects tirzepatide and structurally related peptide analogs.

Tirzepatide is a 39-amino-acid peptide containing:

• A GLP-1-derived peptide backbone.
• Aib substitutions at positions corresponding to X1 and X2.
• A lysine side-chain conjugated to a hydrophilic spacer and C18 diacid.
• A C-terminal primary amide.
• A phenylalanine residue at X3 for the principal commercial molecule.

Tirzepatide is marketed in the United States as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. FDA approved Mounjaro in May 2022 and Zepbound in November 2023. Both products contain tirzepatide as the active ingredient. [1, 2]

The structural elements in claim 10 correspond to tirzepatide:

Claim element	Tirzepatide structure
X1	Aib
X2	Aib
X3	Phe
Lysine modification	Epsilon-amino side-chain conjugation
Spacer	Two acetyl-linked 2-aminoethoxyethoxy units with one gamma-Glu
Fatty-acid segment	C18 diacid
C terminus	Primary amide
Product status	Active ingredient in Mounjaro and Zepbound

How broad are the claims in US 9,474,780?

Claim 1 is a genus claim. It covers compounds with defined substitutions at X1, X2, and X3, a specified lysine conjugate, and a variable linker containing:

• One or two gamma-glutamic acid residues.
• A methylene segment with 10 to 20 carbon units.
• Optional C-terminal amidation.
• A pharmaceutically acceptable salt form.

Claims 2 and 3 narrow X3 to Phe or 1-Nal. Claims 4 through 9 narrow the methylene segment, gamma-glutamate count, and C-terminal amidation.

Claim 10 is the most commercially important composition-of-matter claim. It narrows the compound to:

• Aib at X1.
• Aib at X2.
• One gamma-glutamate residue.
• An 18-carbon methylene segment.
• Phe at X3.
• A C-terminal primary amide.

That combination is the commercial tirzepatide structure.

Claim 11 covers a related analog with two gamma-glutamate residues and 1-Nal at X3. It is not the commercial tirzepatide molecule but can create a separate species-level barrier for closely related analog development.

Claims 12 and 16 cover pharmaceutical compositions. Claims 13, 14, 17, and 18 cover therapeutic use in type 2 diabetes, including coadministration with:

• Metformin.
• Thiazolidinediones.
• Sulfonylureas.
• DPP-4 inhibitors.
• Sodium-glucose cotransporter inhibitors.

What are the key limitations of claim 10?

Claim 10 does not cover every GLP-1 receptor agonist or every dual GIP/GLP-1 agonist. A competing product would need to avoid one or more required structural limitations, such as:

1. The two Aib residues.
2. The exact lysine-side-chain conjugate.
3. The single gamma-glutamate configuration.
4. The C18 methylene segment.
5. The phenylalanine residue at X3.
6. The C-terminal amide.

The claim is therefore strong against literal copies of tirzepatide but narrower than a broad functional claim covering all long-acting incretin agonists.

A generic or follow-on peptide could attempt to design around the claim by changing the fatty-acid chain length, replacing the gamma-glutamate spacer, modifying the peptide backbone, using a different terminal residue, or removing the C-terminal amide. Such changes could affect receptor activity, half-life, manufacturing yield, immunogenicity, or formulation performance.

What is the patent expiration date for US 9,474,780?

The nominal expiration date is approximately August 5, 2034.

The calculation is based on the earliest effective nonprovisional or international filing date associated with the patent family, rather than the provisional priority date. The final enforceable term depends on the patent's recorded patent-term adjustment and any patent-term extension. A patent-term extension based on FDA regulatory review would be evaluated under 35 U.S.C. § 156 and is separate from regulatory exclusivity.

Event	Date
Earliest claimed priority	August 5, 2013
Relevant nonprovisional/PCT filing period	August 5, 2014
Patent issued	October 25, 2016
Nominal 20-year term endpoint	Approximately August 5, 2034
FDA Mounjaro approval	May 13, 2022
FDA Zepbound approval	November 8, 2023

The 2013 priority date does not itself establish the patent-term endpoint. For a post-1995 patent, the term generally runs 20 years from the earliest effective nonprovisional or PCT filing date, subject to adjustment.

Is US 9,474,780 listed in the Orange Book?

The commercial protection for Mounjaro and Zepbound must be evaluated against the FDA Orange Book listings, not against the patent number alone.

The Orange Book identifies patents submitted by an NDA holder for approved drug substances, drug products, and methods of use. A composition-of-matter patent may be listed, but listing depends on whether the patent claims the approved active ingredient, formulation, drug product, or approved method of use under FDA listing rules.

Lilly's tirzepatide protection includes patents issued after US 9,474,780. Publicly reported Mounjaro and Zepbound patent listings include later Lilly patents with expiration dates generally extending into 2036. [3]

The practical distinction is:

Protection category	Typical relevance
US 9,474,780	Foundational peptide composition and use claims
Later composition patents	Species, salts, stereochemistry, or specific tirzepatide forms
Formulation patents	Concentration, excipients, stability, and injectable presentation
Method-of-use patents	Diabetes, obesity, weight reduction, and related metabolic indications
Regulatory exclusivity	FDA exclusivity separate from patent term
Trade secrets	Manufacturing process, purification, scale-up, and analytical controls

An Orange Book listing can trigger a Paragraph IV certification and 30-month stay if an ANDA applicant challenges the listed patent. A patent that is not listed can still be asserted through ordinary patent litigation, but it does not create the same automatic ANDA litigation mechanism.

When does tirzepatide lose exclusivity?

Tirzepatide does not have a single exclusivity-loss date.

Its entry barriers include:

1. FDA regulatory exclusivity.
2. Composition-of-matter patents.
3. Formulation patents.
4. Method-of-use patents.
5. Manufacturing and process patents.
6. Patent litigation and settlement terms.
7. Commercial supply and device constraints.

Mounjaro received new chemical entity exclusivity in connection with its 2022 approval. That exclusivity period is separate from the patent term and does not replace patent protection. Zepbound received separate approval for chronic weight management, but it relies on the same active ingredient and related patent estate. [1, 2]

A generic tirzepatide applicant could face different barriers depending on whether it files an ANDA for the diabetes product, an application directed to a different indication, or a 505(b)(2) application involving a modified presentation.

What Paragraph IV risks exist for tirzepatide?

A tirzepatide ANDA applicant would typically need to address each Orange Book-listed patent through one of four certifications:

• Paragraph I: no patent information has been submitted.
• Paragraph II: the patent has expired.
• Paragraph III: the applicant will wait until patent expiration.
• Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.

For a peptide product, the scientific and legal burden is more complicated than for a conventional small-molecule generic. The applicant must establish pharmaceutical equivalence and bioequivalence, while also reproducing a highly defined peptide structure and injectable product presentation.

Potential Paragraph IV positions could include:

• Noninfringement based on a different molecular structure.
• Invalidity for lack of novelty.
• Obviousness based on prior GLP-1 and fatty-acylated peptide disclosures.
• Lack of written description for the specific claimed species.
• Lack of enablement across the full genus.
• Invalidity of method-of-use claims for previously known diabetes treatment methods.

A literal copy of tirzepatide would face the greatest composition-of-matter risk under claim 10 and related later Lilly patents.

Which companies are challenging tirzepatide patents?

The principal commercial challenger class is expected to consist of generic peptide manufacturers and companies pursuing follow-on incretin products. Publicly available FDA and court records should be reviewed before attributing a specific Paragraph IV filing or litigation position to a named company.

The relevant competitive groups are:

Competitor group	Product strategy	Patent risk
Generic peptide manufacturers	Exact or substantially equivalent tirzepatide	High composition and formulation risk
505(b)(2) applicants	Modified strength, device, formulation, or route	Medium to high, depending on changes
GLP-1 competitors	Semaglutide and related products	Low direct infringement risk
Dual or triple agonist developers	New peptide sequences and conjugates	Depends on structural overlap
Biosimilar-style developers	Follow-on peptide products	No formal biosimilar pathway for tirzepatide

Does tirzepatide have biosimilar risk?

Tirzepatide is a chemically synthesized peptide, not a biologic approved under the Public Health Service Act biologics pathway. A conventional biosimilar application under section 351(k) is therefore not the principal U.S. route.

A follow-on tirzepatide product would more likely use:

• An ANDA under section 505(j), if it qualifies as therapeutically equivalent.
• A 505(b)(2) application for a modified product or clinical presentation.
• A full NDA if the applicant cannot rely sufficiently on Lilly's clinical and regulatory data.

The lack of a formal biosimilar pathway does not eliminate follow-on competition. It changes the regulatory route and may increase the need for comparative analytical, pharmacokinetic, device, or clinical evidence.

What formulation patents protect Mounjaro and Zepbound?

The claims supplied for US 9,474,780 cover the peptide and pharmaceutical compositions but do not define a detailed commercial formulation. The patent does not, based on the supplied claims, claim a specific concentration, preservative system, injection device, or container closure.

Later patents may protect:

• Tirzepatide concentration ranges.
• Buffer systems.
• Preservatives.
• Stabilizers.
• Low-temperature or long-term storage conditions.
• Pre-filled pens and cartridge presentations.
• Multidose delivery systems.
• Manufacturing and purification processes.

A competitor could avoid claim 12 or claim 16 by using a different carrier or excipient only if it also avoids the underlying compound claim. A formulation design-around does not eliminate infringement risk where the formulation contains the exact tirzepatide molecule covered by an unexpired composition claim.

How strong is the patent estate for tirzepatide?

The estate is strong at the active-ingredient level because US 9,474,780 identifies a precise, commercially used peptide structure and includes both composition and use claims. Its principal limitation is age: the patent expires materially earlier than some later Lilly patents.

Factor	Assessment
Exact commercial molecule coverage	Strong
Genus coverage	Moderate to strong
Formulation coverage in supplied claims	Limited
Method-of-use coverage	Moderate
Design-around difficulty	Moderate for novel analogs; high for exact copies
ANDA litigation leverage	Depends on Orange Book listing
Manufacturing barrier	Potentially high even after composition expiry
Biosimilar barrier	Not applicable in the traditional 351(k) sense
Long-term commercial protection	Strengthened by later patent families

The most important business issue is the layering of patents. A competitor may overcome US 9,474,780 but still face later composition, formulation, method-of-use, or process patents.

How does the patent estate compare with semaglutide?

Tirzepatide and semaglutide both use fatty-acid conjugation to extend peptide half-life, but their patent positions differ structurally.

Feature	Tirzepatide	Semaglutide
Principal receptor profile	GIP and GLP-1 agonism	GLP-1 agonism
Commercial sponsor	Eli Lilly	Novo Nordisk
Peptide class	Modified incretin peptide	Modified GLP-1 analog
Lipidation	C18 diacid-based conjugate	Fatty-acid-derived linker and chain
Core patent issue	Exact dual-agonist peptide structure	Exact GLP-1 analog and formulations
Follow-on route	ANDA or 505(b)(2)	ANDA or 505(b)(2)
Biosimilar pathway	Not the standard route	Not the standard route

The two estates are distinct. A semaglutide competitor would not ordinarily avoid tirzepatide patents merely by using semaglutide, because the molecules, peptide backbones, and lipidation architectures differ.

What manufacturing and intellectual-property barriers remain after patent expiry?

Patent expiry will not immediately create a low-cost, interchangeable market.

Tirzepatide manufacturing requires control of:

• Long-chain peptide synthesis.
• Site-specific lysine conjugation.
• Gamma-glutamate incorporation.
• Impurity clearance.
• Aggregation control.
• Peptide identity and potency assays.
• Sterile injectable production.
• Device filling and stability testing.

Process patents and trade secrets may protect coupling order, protecting-group chemistry, purification, refolding or conjugation conditions, and scale-up parameters. These rights can delay entry even where a competitor develops a noninfringing process.

What is the likely generic launch scenario?

The most likely sequence is:

1. Patent and Orange Book review by prospective ANDA sponsors.
2. Paragraph IV certifications against listed patents.
3. Hatch-Waxman litigation and possible 30-month stays.
4. Continued development of nonidentical incretin analogs that avoid tirzepatide claims.
5. Entry of an ANDA or 505(b)(2) product after resolution of listed patents and regulatory exclusivity.
6. Competitive price erosion if multiple approved products achieve substitutable status.

An exact tirzepatide generic would face greater risk than a structurally distinct dual agonist. A new analog may avoid claim 10 but would require independent clinical and regulatory development.

Key Takeaways

• US 9,474,780 covers tirzepatide and related lipidated peptide analogs.
• Claim 10 is the key commercial species claim for tirzepatide.
• The patent's nominal expiration is approximately August 5, 2034, subject to patent-term adjustment or extension.
• Claims 12 and 16 cover pharmaceutical compositions; claims 13, 14, 17, and 18 cover diabetes treatment and combination therapy.
• The patent does not, based on the supplied claims, provide detailed protection for a specific commercial formulation or injection device.
• Later Lilly patents may extend practical market protection beyond this patent's expiration.
• Tirzepatide follow-on products are more likely to proceed through ANDA or 505(b)(2) routes than through a traditional biosimilar application.
• Exact-copy generic risk is high while the composition claims remain enforceable.
• Structurally modified incretin agonists may design around claim 10 but face independent clinical, manufacturing, and patent barriers.
• The omitted structural formula for claim 15 prevents a species-level assessment of claims 15 through 18 beyond their stated composition and method categories.

FAQs

What is the main patent claim covering tirzepatide?

Claim 10 is the principal claim among the claims supplied. It covers the specific Aib/Aib peptide with the one-gamma-glutamate, C18 diacid conjugate, Phe residue, and C-terminal amide corresponding to tirzepatide.

Can a competitor avoid US 9,474,780 by changing the fatty-acid chain?

Potentially, but only if the modified chain falls outside the literal and equivalent scope of the asserted claims and does not infringe later Lilly patents. Claims 4 through 6 specifically narrow the chain length, while claim 1 covers a broader C10-C20 range.

Does US 9,474,780 cover Zepbound?

The patent covers the active ingredient tirzepatide used in Zepbound. It does not, from the supplied claims alone, distinguish between the Mounjaro and Zepbound labels. Indication-specific protection may arise from separate patents and regulatory filings.

Is a tirzepatide generic automatically a biosimilar?

No. Tirzepatide is a synthetic peptide, and a follow-on product would generally use an ANDA, 505(b)(2), or full NDA pathway rather than the standard 351(k) biosimilar pathway.

Why can tirzepatide remain protected after US 9,474,780 expires?

Later patents may cover specific compositions, formulations, methods of use, devices, or manufacturing processes. Those later rights can block or delay commercial entry even after the foundational patent expires.

References

1. U.S. Food and Drug Administration. (2022). FDA approves novel, dual-targeted treatment for type 2 diabetes. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes

2. U.S. Food and Drug Administration. (2023). FDA approves new medication for chronic weight management, first since 2014. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management-first-2014

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,474,780, Peptide compounds. https://patents.google.com/patent/US9474780

5. U.S. Code, 35 U.S.C. §§ 154, 156, and 271(e). (2024). Patent term, patent-term extension, and Hatch-Waxman litigation provisions. https://uscode.house.gov/

Drugs Protected by US Patent 9,474,780

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-007	Jul 28, 2023		RX	Yes	Yes	9,474,780		Y	Y		MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-008	Jul 28, 2023		RX	Yes	Yes	9,474,780		Y	Y		MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-009	Jul 28, 2023		RX	Yes	Yes	9,474,780		Y	Y		MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

International Family Members for US Patent 9,474,780

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3242887		CA 2023 00005	Denmark
European Patent Office	3242887		301217	Netherlands
European Patent Office	3242887		PA2023504	Lithuania